What is 4D Molecular Therapeutics's D&A?

4D Molecular Therapeutics (FDMT) reported D&A of $1.27M in Q1 2026.

How has 4D Molecular Therapeutics's D&A changed year-over-year?

4D Molecular Therapeutics's D&A increased by 20.7% year-over-year, from $1.05M to $1.27M.

What is the long-term trend for 4D Molecular Therapeutics's D&A?

Over 4 years (2021 to 2025), 4D Molecular Therapeutics's D&A has grown at a 32.5% compound annual growth rate (CAGR), from $1.52M to $4.69M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

4D Molecular Therapeutics FDMT D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

EyePoint, Inc. EYPT

$636K+28.0%

RegenxbioRGNX

$3.86M-2.5%

MeiraGTx Holdings plcMGTX

$3.01M-2.4%

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's D&A?: 4D Molecular Therapeutics (FDMT) reported D&A of $1.27M in Q1 2026.
How has 4D Molecular Therapeutics's D&A changed year-over-year?: 4D Molecular Therapeutics's D&A increased by 20.7% year-over-year, from $1.05M to $1.27M.
What is the long-term trend for 4D Molecular Therapeutics's D&A?: Over 4 years (2021 to 2025), 4D Molecular Therapeutics's D&A has grown at a 32.5% compound annual growth rate (CAGR), from $1.52M to $4.69M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.